Which has preferable earnings & valuation, AAPG or CAPR?

Capricor Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascentage Pharma Group International $82.10M 20.80 -$177.71M N/A N/A Capricor Therapeutics $22.27M 25.04 -$105.04M -$2.45 N/A

Is AAPG or CAPR more profitable?

Ascentage Pharma Group International's return on equity of 0.00% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ascentage Pharma Group International N/A N/A N/A Capricor Therapeutics N/A -56.60% -43.97%

Is CAPR or BCAX more profitable?

Bicara Therapeutics' return on equity of -41.49% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -56.60% -43.97% Bicara Therapeutics N/A -41.49% -38.59%

Does the media refer more to CAPR or BCAX?

In the previous week, Capricor Therapeutics had 50 more articles in the media than Bicara Therapeutics. MarketBeat recorded 58 mentions for Capricor Therapeutics and 8 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 1.14 beat Capricor Therapeutics' score of 0.18 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 45 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Bicara Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CAPR or TYRA more profitable?

Tyra Biosciences' return on equity of -46.39% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -56.60% -43.97% Tyra Biosciences N/A -46.39% -43.07%

Does the media favor CAPR or TYRA?

In the previous week, Capricor Therapeutics had 52 more articles in the media than Tyra Biosciences. MarketBeat recorded 58 mentions for Capricor Therapeutics and 6 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.77 beat Capricor Therapeutics' score of 0.18 indicating that Tyra Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 45 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Tyra Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is CAPR or TRAX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Capricor Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -56.60% -43.97% First Tracks Biotherapeutics N/A N/A N/A

Is CAPR or INBX more profitable?

Capricor Therapeutics' return on equity of -56.60% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Capricor Therapeutics N/A -56.60% -43.97% Inhibrx Biosciences N/A -563.90% -83.48%

Does the media favor CAPR or INBX?

In the previous week, Capricor Therapeutics had 38 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 58 mentions for Capricor Therapeutics and 20 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.19 beat Capricor Therapeutics' score of 0.18 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 45 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Inhibrx Biosciences 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Capricor Therapeutics (CAPR) Competitors

$9.59 -0.47 (-4.67%)

As of 08/28/2026 04:00 PM Eastern

Compare

CAPR vs. AAPG, BCAX, TYRA, TRAX, and INBX

Should you buy Capricor Therapeutics stock or one of its competitors? Capricor Therapeutics's main competitors and comparable companies include Ascentage Pharma Group International (AAPG), Bicara Therapeutics (BCAX), Tyra Biosciences (TYRA), First Tracks Biotherapeutics (TRAX), and Inhibrx Biosciences (INBX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Capricor Therapeutics compare to Ascentage Pharma Group International?

Ascentage Pharma Group International (NASDAQ:AAPG) and Capricor Therapeutics (NASDAQ:CAPR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

In the previous week, Capricor Therapeutics had 53 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 58 mentions for Capricor Therapeutics and 5 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 0.78 beat Capricor Therapeutics' score of 0.18 indicating that Ascentage Pharma Group International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascentage Pharma Group International	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Capricor Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	45 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Ascentage Pharma Group International currently has a consensus target price of $46.43, suggesting a potential upside of 153.99%. Capricor Therapeutics has a consensus target price of $29.15, suggesting a potential upside of 203.96%. Given Capricor Therapeutics' higher probable upside, analysts plainly believe Capricor Therapeutics is more favorable than Ascentage Pharma Group International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascentage Pharma Group International	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.20
Capricor Therapeutics	1 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.09

Ascentage Pharma Group International has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Capricor Therapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

21.7% of Capricor Therapeutics shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ascentage Pharma Group International's return on equity of 0.00% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascentage Pharma Group International	N/A	N/A	N/A
Capricor Therapeutics	N/A	-56.60%	-43.97%

Capricor Therapeutics has lower revenue, but higher earnings than Ascentage Pharma Group International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascentage Pharma Group International	$82.10M	20.80	-$177.71M	N/A	N/A
Capricor Therapeutics	$22.27M	25.04	-$105.04M	-$2.45	N/A

Summary

Ascentage Pharma Group International and Capricor Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Capricor Therapeutics compare to Bicara Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Capricor Therapeutics currently has a consensus target price of $29.15, indicating a potential upside of 203.96%. Bicara Therapeutics has a consensus target price of $32.64, indicating a potential upside of 39.29%. Given Capricor Therapeutics' higher possible upside, equities analysts clearly believe Capricor Therapeutics is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.09
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.80

Capricor Therapeutics has higher revenue and earnings than Bicara Therapeutics. Bicara Therapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	25.04	-$105.04M	-$2.45	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$3.10	N/A

Capricor Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.75, meaning that its share price is 175% less volatile than the broader market.

In the previous week, Capricor Therapeutics had 50 more articles in the media than Bicara Therapeutics. MarketBeat recorded 58 mentions for Capricor Therapeutics and 8 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 1.14 beat Capricor Therapeutics' score of 0.18 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	45 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Bicara Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

21.7% of Capricor Therapeutics shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bicara Therapeutics' return on equity of -41.49% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
Bicara Therapeutics	N/A	-41.49%	-38.59%

Summary

Capricor Therapeutics beats Bicara Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Capricor Therapeutics compare to Tyra Biosciences?

Capricor Therapeutics (NASDAQ:CAPR) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Capricor Therapeutics had 52 more articles in the media than Tyra Biosciences. MarketBeat recorded 58 mentions for Capricor Therapeutics and 6 mentions for Tyra Biosciences. Tyra Biosciences' average media sentiment score of 1.77 beat Capricor Therapeutics' score of 0.18 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	45 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tyra Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Capricor Therapeutics presently has a consensus price target of $29.15, indicating a potential upside of 203.96%. Tyra Biosciences has a consensus price target of $46.90, indicating a potential upside of 88.05%. Given Capricor Therapeutics' higher possible upside, equities analysts clearly believe Capricor Therapeutics is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.09
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Tyra Biosciences' return on equity of -46.39% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
Tyra Biosciences	N/A	-46.39%	-43.07%

Capricor Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Capricor Therapeutics has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	25.04	-$105.04M	-$2.45	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.40	N/A

Summary

Tyra Biosciences beats Capricor Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Capricor Therapeutics compare to First Tracks Biotherapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

21.7% of Capricor Therapeutics shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Capricor Therapeutics had 55 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 58 mentions for Capricor Therapeutics and 3 mentions for First Tracks Biotherapeutics. First Tracks Biotherapeutics' average media sentiment score of 0.94 beat Capricor Therapeutics' score of 0.18 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	45 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
First Tracks Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

First Tracks Biotherapeutics has lower revenue, but higher earnings than Capricor Therapeutics. First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	25.04	-$105.04M	-$2.45	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$1.84	N/A

Capricor Therapeutics currently has a consensus target price of $29.15, indicating a potential upside of 203.96%. First Tracks Biotherapeutics has a consensus target price of $63.00, indicating a potential upside of 50.50%. Given Capricor Therapeutics' higher probable upside, equities research analysts plainly believe Capricor Therapeutics is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.09
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

First Tracks Biotherapeutics' return on equity of 0.00% beat Capricor Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
First Tracks Biotherapeutics	N/A	N/A	N/A

Summary

Capricor Therapeutics and First Tracks Biotherapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Capricor Therapeutics compare to Inhibrx Biosciences?

Capricor Therapeutics (NASDAQ:CAPR) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Capricor Therapeutics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.51, suggesting that its stock price is 251% more volatile than the broader market.

In the previous week, Capricor Therapeutics had 38 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 58 mentions for Capricor Therapeutics and 20 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.19 beat Capricor Therapeutics' score of 0.18 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	45 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Inhibrx Biosciences	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Capricor Therapeutics' return on equity of -56.60% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 9.2% of Capricor Therapeutics shares are owned by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Capricor Therapeutics has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27M	25.04	-$105.04M	-$2.45	N/A
Inhibrx Biosciences	N/A	N/A	-$140.05M	-$8.88	N/A

Capricor Therapeutics currently has a consensus target price of $29.15, suggesting a potential upside of 203.96%. Inhibrx Biosciences has a consensus target price of $197.50, suggesting a potential upside of 60.04%. Given Capricor Therapeutics' higher probable upside, equities research analysts plainly believe Capricor Therapeutics is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	8 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.09
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Capricor Therapeutics beats Inhibrx Biosciences on 8 of the 14 factors compared between the two stocks.

Get Capricor Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAPR vs. The Competition

Export

Metric	Capricor Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$557.55M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-3.91	11.62	273.16	25.45
Price / Sales	25.04	1,295.88	605.00	76.62
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	2.26	16.53	12.98	6.14
Net Income	-$105.04M	-$22.80M	$3.48B	$348.86M
7 Day Performance	52.46%	-0.31%	0.13%	-0.80%
1 Month Performance	128.88%	9.80%	7.08%	4.13%
1 Year Performance	52.71%	55.66%	24.67%	15.17%

Capricor Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAPR Capricor Therapeutics	3.0634 of 5 stars	$9.59 -4.7%	$29.15 +204.0%	+52.7%	$557.55M	$22.27M	N/A	101	Trending News Analyst Upgrade Options Volume Gap Down
AAPG Ascentage Pharma Group International	4.2008 of 5 stars	$16.95 +1.4%	$46.43 +173.9%	-57.0%	$1.56B	$82.10M	N/A	600	News Coverage Gap Down
BCAX Bicara Therapeutics	2.3885 of 5 stars	$24.58 +4.2%	$32.64 +32.8%	+96.2%	$1.56B	N/A	N/A	32
TYRA Tyra Biosciences	2.3431 of 5 stars	$26.69 +2.3%	$46.90 +75.7%	+96.8%	$1.56B	N/A	N/A	20	News Coverage Positive News
TRAX First Tracks Biotherapeutics	3.3506 of 5 stars	$45.11 +4.2%	$63.00 +39.7%	N/A	$1.55B	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAPR) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Capricor Therapeutics (CAPR) Competitors

CAPR vs. AAPG, BCAX, TYRA, TRAX, and INBX

How does Capricor Therapeutics compare to Ascentage Pharma Group International?

Summary

How does Capricor Therapeutics compare to Bicara Therapeutics?

Summary

How does Capricor Therapeutics compare to Tyra Biosciences?

Summary

How does Capricor Therapeutics compare to First Tracks Biotherapeutics?

Summary

How does Capricor Therapeutics compare to Inhibrx Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Capricor Therapeutics (CAPR) Competitors

CAPR vs. AAPG, BCAX, TYRA, TRAX, and INBX

How does Capricor Therapeutics compare to Ascentage Pharma Group International?

Does the media prefer AAPG or CAPR?

Do analysts recommend AAPG or CAPR?

Which has more volatility and risk, AAPG or CAPR?

Do institutionals & insiders have more ownership in AAPG or CAPR?

Is AAPG or CAPR more profitable?

Which has preferable earnings & valuation, AAPG or CAPR?

Summary

How does Capricor Therapeutics compare to Bicara Therapeutics?

Do analysts recommend CAPR or BCAX?

Which has higher earnings & valuation, CAPR or BCAX?

Which has more volatility & risk, CAPR or BCAX?

Does the media refer more to CAPR or BCAX?

Do institutionals and insiders believe in CAPR or BCAX?

Is CAPR or BCAX more profitable?

Summary

How does Capricor Therapeutics compare to Tyra Biosciences?

Does the media favor CAPR or TYRA?

Do insiders and institutionals believe in CAPR or TYRA?

Do analysts rate CAPR or TYRA?

Is CAPR or TYRA more profitable?

Which has more risk & volatility, CAPR or TYRA?

Which has preferable valuation and earnings, CAPR or TYRA?

Summary

How does Capricor Therapeutics compare to First Tracks Biotherapeutics?

Do insiders & institutionals believe in CAPR or TRAX?

Does the media prefer CAPR or TRAX?

Which has stronger earnings & valuation, CAPR or TRAX?

Do analysts rate CAPR or TRAX?

Is CAPR or TRAX more profitable?

Summary

How does Capricor Therapeutics compare to Inhibrx Biosciences?

Which has more risk and volatility, CAPR or INBX?

Does the media favor CAPR or INBX?

Is CAPR or INBX more profitable?

Do insiders and institutionals have more ownership in CAPR or INBX?

Which has better valuation & earnings, CAPR or INBX?

Do analysts prefer CAPR or INBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR vs. The Competition

Capricor Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools